L
Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biotechnology company, focuses on the discovery and early-stage development of pharmaceuticals for
About Ligand Pharmaceuticals
Ligand Pharmaceuticals was founded in 1987 by Brook Byers, a partner at Kleiner Perkins, and a team of scientists including Ronald Evans from the Salk Institute. The company was established with a vision to innovate in the field of biopharmaceuticals, focusing on drug discovery and development through partnerships and licensing.
Over the years, Ligand Pharmaceuticals has become known for its unique business model, which involves acquiring royalty rights to promising drugs and technologies. This approach has allowed Ligand to build a diverse portfolio of assets without the high costs associated with traditional drug development.
A significant milestone in Ligand's journey was its acquisition of APEIRON Biologics AG in 2024 for $100 million. This acquisition provided Ligand with the royalty rights to QARZIBA®, a commercial oncology drug marketed in 35 countries. This strategic move not only expanded Ligand's portfolio but also reinforced its position in the global pharmaceutical market.
Ligand's journey reflects a commitment to innovation and strategic growth, leveraging partnerships and acquisitions to drive success in the competitive biopharmaceutical industry. Today, Ligand Pharmaceuticals continues to play a pivotal role in advancing medical science through its innovative business model and strategic acquisitions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1987
- Headquarters
- Jupiter, United States
- Listing
- IPO 1994
- Employees
- 133
- Open positions
- None listed
- Dealroom signal
- 39.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 27 companies, latest Sep 2026
- Capital deployed
- $265M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLE✓Other financing | Jun 2026 | $625M | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Aug 2025 | $400M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Ligand Pharmaceuticals is 5.2K monthly website visits, up 18.2% over the last three months. Ligand Pharmaceuticals's team declined 0.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AvenCellWatertown, United StatesAvenCell develops next generation immunotherapies against hard-to-treat blood and solid tumor cancers
$448Mvaluation
Primrose BioSan Diego, United StatesWorks to become a leading provider of genetic solutions for microbial improvement
→
AgenusLexington, United StatesOur goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants
$401Mvaluation
ZERIONBirkerød, DenmarkA pharmaceutical company aspiring to transform the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential
$4.8Mvaluation
ArecorLittle Chesterford, United KingdomProprietary formulation technology enhancing existing therapeutic products
$32Mvaluation
Orchestra BioMedNew Hope, United StatesBiomedical innovation company
$282Mvaluation
Palvella TherapeuticsRadnor Township, United StatesRare disease biopharmaceutical company
$1.9Bvaluation
invIOsVienna, AustriaInnovative biotechnology company developing personalized cancer treatments with next-generation technologies
$36Mvaluation
APEIRON BiologicsVienna, AustriaFocused on the discovery and development of novel cancer immunotherapies
$100Mvaluation
TT
Tolerance TherapeuticsChicago, United States
$20Mvaluation
OmniAbEmeryville, United StatesAntibody discovery company
$663Mvaluation
ICAgenDurham, United StatesInnovative ion channel drug discovery platform enabling targeted therapeutics for pharmaceutical and biotech partners
$20Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Venrock
Series B and later4 investors entered at this stage
Castle Creek Biosciences
Paragon Biosciences
Valor Equity Partners
XOMA
Other known investors3 additional known investors
InterWest Partners
KU Innovation Park
Signet Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ligand Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ligand Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.